Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Circulation. Arrhythmia and electrophysiology Année : 2017

Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy

Résumé

Rapid advances in allele-specific silencing by RNA interference established a strategy of choice to cure dominant inherited diseases by targeting mutant alleles. We used this strategy for autosomal-dominant centronuclear myopathy (CNM), a rare neuromuscular disorder without available treatment due to heterozygous mutations in the DNM2 gene encoding Dynamin 2. Allele-specific siRNA sequences were developed in order to specifically knock down the human and murine DNM2-mRNA harbouring the p.R465W mutation without affecting the wild-type allele. Functional restoration was achieved in muscle from a knock-in mouse model and in patient-derived fibroblasts, both expressing the most frequently encountered mutation in patients. Restoring either muscle force in a CNM mouse model or DNM2 function in patient-derived cells is an essential breakthrough towards future gene-based therapy for dominant centronuclear myopathy.

Dates et versions

hal-04001377 , version 1 (22-02-2023)

Identifiants

Citer

Delphine Trochet, Bernard Prudhon, Maud Beuvin, Cécile Peccate, Stéphanie Lorain, et al.. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy. Circulation. Arrhythmia and electrophysiology, 2017, 10 (12), pp.428-431. ⟨10.15252/emmm.201707988⟩. ⟨hal-04001377⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More